CN113755581A - Nucleic acid composition, kit and method for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry - Google Patents
Nucleic acid composition, kit and method for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry Download PDFInfo
- Publication number
- CN113755581A CN113755581A CN202111134097.1A CN202111134097A CN113755581A CN 113755581 A CN113755581 A CN 113755581A CN 202111134097 A CN202111134097 A CN 202111134097A CN 113755581 A CN113755581 A CN 113755581A
- Authority
- CN
- China
- Prior art keywords
- ambystoma
- dna
- nucleic acid
- jeffersonianum
- laterale
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 27
- 229940079593 drug Drugs 0.000 title claims abstract description 25
- 208000020016 psychiatric disease Diseases 0.000 title claims abstract description 24
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 22
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 239000011159 matrix material Substances 0.000 title claims abstract description 16
- 238000003795 desorption Methods 0.000 title claims abstract description 15
- 238000001269 time-of-flight mass spectrometry Methods 0.000 title claims abstract description 15
- 238000001514 detection method Methods 0.000 claims abstract description 11
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 2
- 108020004414 DNA Proteins 0.000 claims description 134
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 7
- 238000011033 desalting Methods 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 238000012408 PCR amplification Methods 0.000 claims description 2
- 239000007795 chemical reaction product Substances 0.000 claims description 2
- 102200026593 rs1065852 Human genes 0.000 claims description 2
- 102200026617 rs1135840 Human genes 0.000 claims description 2
- 102200026635 rs16947 Human genes 0.000 claims description 2
- 102220005865 rs5030865 Human genes 0.000 claims description 2
- 229940001470 psychoactive drug Drugs 0.000 claims 1
- 239000004089 psychotropic agent Substances 0.000 claims 1
- 102200158452 rs1902023 Human genes 0.000 claims 1
- 102220005866 rs35742686 Human genes 0.000 claims 1
- 238000013461 design Methods 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 206010067484 Adverse reaction Diseases 0.000 abstract description 4
- 230000006838 adverse reaction Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 4
- 230000004907 flux Effects 0.000 abstract description 4
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 230000003556 anti-epileptic effect Effects 0.000 abstract description 2
- 239000001961 anticonvulsive agent Substances 0.000 abstract description 2
- 239000000935 antidepressant agent Substances 0.000 abstract description 2
- 229940005513 antidepressants Drugs 0.000 abstract description 2
- 229960003965 antiepileptics Drugs 0.000 abstract description 2
- 239000000164 antipsychotic agent Substances 0.000 abstract description 2
- 229940005529 antipsychotics Drugs 0.000 abstract description 2
- 239000002249 anxiolytic agent Substances 0.000 abstract description 2
- 230000000949 anxiolytic effect Effects 0.000 abstract description 2
- 229940005530 anxiolytics Drugs 0.000 abstract description 2
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 230000004799 sedative–hypnotic effect Effects 0.000 abstract description 2
- 241000269335 Ambystoma laterale x Ambystoma jeffersonianum Species 0.000 description 126
- 239000000523 sample Substances 0.000 description 19
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 6
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007403 mPCR Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000013138 Drug Receptors Human genes 0.000 description 1
- 108010065556 Drug Receptors Proteins 0.000 description 1
- 102000012078 E2F2 Transcription Factor Human genes 0.000 description 1
- 108010036466 E2F2 Transcription Factor Proteins 0.000 description 1
- 101000595467 Homo sapiens T-complex protein 1 subunit gamma Proteins 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a nucleic acid composition, a kit and a method for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry. The nucleic acid composition comprises an upstream primer and a downstream primer of 42 SNP sites, and the nucleic acid sequence is shown as SEQ ID NO. 1-84. The application covers genes related to pharmacokinetics, pharmacodynamics and/or drug severe adverse reactions, and the site is selected according to authoritative literature reports and guidelines, and the primer design and detection are carried out on 42 SNP sites of 30 genes related to the medication of mental diseases including antipsychotics, antidepressants, anxiolytics, sedative-hypnotics and antiepileptics, so that guidance can be provided for accurate medication of the diseases. Compared with the existing method, the method has the advantages of rapidness, sensitivity, high flux, low cost and the like.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a nucleic acid composition, a kit and a method for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry.
Background
Mental diseases become high-incidence diseases in China, and more than 17 percent of adults in China are seriously troubled by the mental diseases such as depression, schizophrenia and the like according to statistics. Mental diseases are diseases which are clinically manifested by dysfunction of brain, and different degrees of disorders of mental activities such as cognition, emotion, will, behavior and the like, under the influence of various biological, psychological and social environmental factors. The major categories of the mental diseases include light mental diseases and severe mental diseases, the common light mental diseases include depression, anxiety, obsessive compulsive disorder and the like, and the common severe mental diseases include schizophrenia and the like.
At present, the treatment mode of mental diseases is mainly drug treatment, although the types of drugs for resisting mental diseases are many, the clinical treatment effect is not ideal, 30-50% of patients have poor response to the drugs, and even can face a plurality of adverse reactions, so the life quality of the patients is seriously influenced. In recent years, pharmacogenomics has been rapidly developed, which is a subject for studying the difference in drug dose response among and among populations caused by drug metabolism (pharmacokinetic effect) and polymorphism of drug receptors and other effectors (pharmacokinetic effect), thereby solving the clinical problem of why different patients have different responses to the same drug. It can achieve the purpose of individual treatment by guiding the selection and dosage adjustment of the medicine through the detection of related genes of the curative effect and the adverse reaction of the medicine.
At present, the related gene detection methods of the mental drugs mainly comprise Sanger sequencing, a probe method, a gene chip method, an ARMS method and the like. However, the methods have the defects of low flux, few detection sites, high price and the like, and particularly, the ARMS method is difficult in primer design and has high requirements on technical personnel. Therefore, the inventor considers that the product for detecting the SNP related to the psychosis medication with high speed, sensitivity, high flux and low cost is very necessary.
Disclosure of Invention
In order to solve the technical problems, the invention provides a nucleic acid composition, a kit and a method for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry.
The invention is realized by the following technical scheme.
A nucleic acid composition for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry, which comprises an upstream primer and a downstream primer of 42 SNP loci, wherein the 42 SNP loci are rs1799978, rs4986893, rs6444970, rs28371725, rs1051740, rs144012689, rs1135840, rs6295, rs4713916, rs389209, rs1045642, rs1414334, rs489693, rs3087374, rs762551, rs1057910, rs1799732, rs9291547, rs1471786, rs 776776776746, rs 35267486, rs 2304014014014016, rs 1902022022023, rs5030865, rs16947, rs1065852, rs334558, rs 49223042239122, rs 18097, rs 1389273, rs1061235, rs1799930, rs 107425, 95195425, 95195439, rs 429780, rs 4297457980; the nucleic acid sequences of the upstream primer and the downstream primer of the 42 SNP sites are shown in SEQ ID NO. 1-84.
Further, the nucleic acid composition also comprises 42 extension primers, and the nucleic acid sequences of the extension primers are shown as SEQ ID NO. 85-126.
A kit for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry comprises the nucleic acid composition.
A detection method for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry comprises the following steps:
s1, carrying out PCR amplification on a DNA sample by using the nucleic acid composition as a primer;
s2, carrying out SAP reaction on the amplification product obtained in the step S1;
s3, adopting the extension primer to carry out extension reaction on the reaction product obtained in the step S2;
and S4, desalting the sample obtained in the step S3, spotting the sample on a chip, and then performing matrix-assisted laser desorption time-of-flight mass spectrometry.
The present application has the following advantageous effects.
The application covers genes related to pharmacokinetics, pharmacodynamics and/or drug severe adverse reactions, and the site is selected according to authoritative literature reports and guidelines, and the primer design and detection are carried out on 42 SNP sites of 30 genes related to the medication of mental diseases including antipsychotics, antidepressants, anxiolytics, sedative-hypnotics and antiepileptics, so that guidance can be provided for accurate medication of the diseases. Compared with the existing method, the method has the advantages of rapidness, sensitivity, high flux, low cost and the like.
Drawings
FIG. 1 is a graph showing the typing effect of 3 human DNA samples tested by the present invention (where E1F1 is the 1 st well 2 nd well of sample 1, E2F2 is the 1 st well 2 nd well of sample 2, and E3F3 is the 1 st well 2 nd well of sample 3);
FIG. 2 is a graph showing the results of the normal peak of rs7997012 detected in samples 1 and 2 according to the present invention (wherein A is a graph showing the results of the normal peak of rs7997012 detected in sample 2; B is a graph showing the results of the normal peak of rs7997012 detected in sample 1);
FIG. 3 is a cluster plot of rs7997012 detected on 3 human DNA samples using the present invention.
Detailed Description
The present invention will be further described with reference to the following examples.
The method adopts EDTA anticoagulation blood sample, uses a full-automatic nucleic acid extractor to extract DNA, uses a PCR (polymerase chain reaction) instrument to realize amplification, SAP (super-absorbent polymer) reaction and extension reaction, transfers the obtained analysis product to a detection chip after desalting, and uses a MassARRAY system (comprising a MassARRAY Analyzer and an integrated liquid processor called a Chip Preparation Module (CPM)) to detect the chip and realize result interpretation.
Further, the detection method adopted by the application is multiplex PCR combined with nucleic acid flight mass spectrometry. The 42 target sequences are divided into two systems (1 st hole and 2 nd hole), the 42 target sequences are simultaneously amplified in the two systems through multiplex PCR, and then a specific extension primer aiming at each SNP sequence is added to extend 1 base on the SNP site. The prepared sample analyte and a chip matrix are co-crystallized and then are excited by strong laser in a vacuum tube of a mass spectrometer, nucleic acid molecules are desorbed into singly charged ions and fly in an electric field, and according to the principle that the ion flight time is inversely proportional to the ion mass, the accurate molecular weight of the sample analyte is obtained by detecting the flight time of the nucleic acid molecules in the vacuum tube, so that the SNP site information is detected.
The specific process is as follows:
first, primer design
According to the method, 42 SNP loci of 30 genes are obtained by screening according to the reports and the guidelines of the authoritative documents, and the specific information is shown in Table 1.
TABLE 1
The primer design is carried out on 42 SNP sites obtained by screening, and the upstream primer and the downstream primer of the 42 SNP sites are shown in a table 2.
TABLE 2
The application carries out primer design aiming at 42 SNP sites obtained by screening, and the extension primers of the 42 SNP sites are shown in Table 3.
TABLE 3
Second, the experimental procedure
DNA extraction
Venous blood was collected using an EDTA anticoagulation tube, and DNA was extracted using a Qiagen nucleic acid extractor, following the instructions of the Qiagen DNA minikit.
PCR reaction and conditions
PCR was carried out using an Eppendorf PCR instrument under the following conditions.
In a new 1.5mL EP tube, the following reaction system was arranged
The 96-well plate was placed on a PCR instrument for the following thermal cycling: 2 minutes at 95 ℃; 45 cycles of 95 ℃ for 30 seconds, 56 ℃ for 30 seconds and 72 ℃ for 60 seconds; 5 minutes at 72 ℃; keeping the temperature at 4 ℃.
SAP reaction and conditions
After the PCR reaction is finished, the PCR product is treated with SAP to remove free dNTPs in the system.
The following alkaline phosphatase treatment reaction solution was prepared
Mu.l of the alkaline phosphatase-treated reaction solution was mixed with 5. mu.l of the PCR product, and then SAP reaction was carried out using an Eppendorf PCR apparatus under the following conditions: 40 minutes at 37 ℃; 5 minutes at 85 ℃; keeping the temperature at 4 ℃.
4. Extension reaction and conditions
After the alkaline phosphatase treatment, a single base extension reaction was performed.
The following single-base extension reaction solution was prepared
Mu.l of the single-base extension reaction solution was mixed with 7. mu.l of the SAP-treated PCR product, and then extension reaction was performed using an Eppendorf PCR apparatus under the following conditions:
5. sample desalting and on-machine analysis
The resin was washed 3 times with clean water, and the washed resin was transferred to the resin tank in CPM with a certain amount of purified water (28g resin in 16mL purified water). HPLC water 41uL was added to the sample wells of a 96-well plate, membrane-sealed, and then centrifuged, and placed into the CPM. The chip plate was transferred to the CPM chip slot with tweezers. With reference to the operational description, the parameters are set.
The CPM will program sample desalt, spot to chip and mass spectrometer to obtain data.
The results are shown in Table 4 and the analytical reports are shown in tables 5-9.
The application detects 3 human DNA samples, and the detection results are shown in figures 1-3.
In the peak result chart, the heterozygote type sample has two peaks, and the homozygote type has only one peak. Fig. 2 shows that sample 2rs7997012 was typed GG and sample 1rs7997012 was typed AG.
The cluster plot shows the typing of all test samples at this site. Fig. 3 shows the typing of rs7997012 of the 3 human-derived samples tested, two are GG, one is AG, o indicates the currently selected sample, in this figure is sample 2, indicating that rs7997012 is typed as GG.
TABLE 4
TABLE 5
TABLE 6
TABLE 7
TABLE 8
TABLE 9
Sequence listing
<110> Xiamen city Xianye hospital (Xiamen city mental health center)
<120> nucleic acid composition, kit and method for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry
<160> 126
<170> SIPOSequenceListing 1.0
<210> 1
<211> 29
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 1
acgttggatg actgcgctcc cacccacac 29
<210> 2
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 2
acgttggatg tcaaaggaga agactggcga 30
<210> 3
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 3
acgttggatg aacatcagga ttgtaagcac 30
<210> 4
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 4
acgttggatg gactgtaagt ggtttctcag 30
<210> 5
<211> 29
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 5
acgttggatg actgatcctc tgtagggtt 29
<210> 6
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 6
acgttggatg tgccaagaac ctgtcaggtc 30
<210> 7
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 7
acgttggatg tcccagcaaa gttcatgggc 30
<210> 8
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 8
acgttggatg tgatcctaca tccggatgtg 30
<210> 9
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 9
acgttggatg ttgactggaa gaagcaggtg 30
<210> 10
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 10
acgttggatg ctggcgtttt gcaaacatac 30
<210> 11
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 11
acgttggatg acatgtgctg cacaaaagag 30
<210> 12
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 12
acgttggatg ctgcctcatt actgggaagc 30
<210> 13
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 13
acgttggatg actaggtacc ccattctagc 30
<210> 14
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 14
acgttggatg ccatggtgtc tttgctttcc 30
<210> 15
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 15
acgttggatg gtcagtctcc caattattgc 30
<210> 16
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 16
acgttggatg cgagaacgga ggtagctttt 30
<210> 17
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 17
acgttggatg tatctggcaa ccctaacctc 30
<210> 18
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 18
acgttggatg cctaacgaga tagtgaggag 30
<210> 19
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 19
acgttggatg ttgtccaaga gaccgttggg 30
<210> 20
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 20
acgttggatg tttgtgccgc cttcgccaac 30
<210> 21
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 21
acgttggatg aaggcatgta tgttggcctc 30
<210> 22
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 22
acgttggatg gctgagaaca ttgcctatgg 30
<210> 23
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 23
acgttggatg ggcctcatct acccaataac 30
<210> 24
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 24
acgttggatg agcctaaagt aggccttgtc 30
<210> 25
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 25
acgttggatg ccagatttgg tcaatacagg 30
<210> 26
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 26
acgttggatg atacctgcca cgctgtaaac 30
<210> 27
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 27
acgttggatg agcaaataca gagcctccag 30
<210> 28
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 28
acgttggatg ttgaactcac caaaggctcc 30
<210> 29
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 29
acgttggatg gaatcttgag gctcctttcc 30
<210> 30
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 30
acgttggatg ctaagctcca tctaccatgc 30
<210> 31
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 31
acgttggatg atgcaagaca ggagccacat 30
<210> 32
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 32
acgttggatg tgtcacaggt cactgcatgg 30
<210> 33
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 33
acgttggatg aaaggagctg tacctcctcg 30
<210> 34
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 34
acgttggatg tcaaaacaag ggatggcgga 30
<210> 35
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 35
acgttggatg cactgtatct tgcttttccc 30
<210> 36
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 36
acgttggatg ttgacagcct tgtatatgag 30
<210> 37
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 37
acgttggatg ttgggcagat catcaccatc 30
<210> 38
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 38
acgttggatg tttactggcg gtaatccctg 30
<210> 39
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 39
acgttggatg gtaatgtggt ccaaacaggg 30
<210> 40
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 40
acgttggatg atgtaccacc cagcttaacg 30
<210> 41
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 41
acgttggatg tctcaccttc tccatctctg 30
<210> 42
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 42
acgttggatg agctggatga gctgctaact 30
<210> 43
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 43
acgttggatg gggtggctga agtgttttac 30
<210> 44
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 44
acgttggatg agagcatcat tttgcccctc 30
<210> 45
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 45
acgttggatg ccatatatcc atctatcgag 30
<210> 46
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 46
acgttggatg tctactcttg tcaatgccag 30
<210> 47
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 47
acgttggatg ttgtccaaga gaccgttggg 30
<210> 48
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 48
acgttggatg tttgtgccgc cttcgccaac 30
<210> 49
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 49
acgttggatg agagaacagg tcagccacca 30
<210> 50
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 50
acgttggatg ttctgtcccg agtatgctct 30
<210> 51
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 51
acgttggatg acctggtcga agcagtatgg 30
<210> 52
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 52
acgttggatg catttggtag tgaggcaggt 30
<210> 53
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 53
acgttggatg ttcctttgtc acttggcccg 30
<210> 54
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 54
acgttggatg agacagcgct cctcacacag 30
<210> 55
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 55
acgttggatg cacttcatcc acgtgaagcc 30
<210> 56
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 56
acgttggatg aaaactcgta gaaagagccg 30
<210> 57
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 57
acgttggatg acacagccat cctcaaagtg 30
<210> 58
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 58
acgttggatg acatgatgcc ctgctttcgg 30
<210> 59
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 59
acgttggatg gctgatccac atggagttac 30
<210> 60
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 60
acgttggatg ccagaaggac cacagaaaca 30
<210> 61
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 61
acgttggatg tggtcttggt gttgatggag 30
<210> 62
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 62
acgttggatg atcgcatgac agtggtacag 30
<210> 63
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 63
acgttggatg ttcctgccct tccctttgtg 30
<210> 64
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 64
acgttggatg cctcctcaca ttatgcctac 30
<210> 65
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 65
acgttggatg cctgccaaag aagaaacacc 30
<210> 66
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 66
acgttggatg aagatgttgg agacgtctgc 30
<210> 67
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 67
acgttggatg cgtaacgcga tcaaattcct 30
<210> 68
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 68
acgttggatg gactgctgct cctcctcagt 30
<210> 69
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 69
acgttggatg atacatgatc ctaagggcag 30
<210> 70
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 70
acgttggatg tccacagtgc tgtcagaatc 30
<210> 71
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 71
acgttggatg ctgctgtgtg gctgaatgtc 30
<210> 72
<211> 31
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 72
acgttggatg catctggaag gtattgttga c 31
<210> 73
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 73
acgttggatg gtaggtacaa agagcctatc 30
<210> 74
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 74
acgttggatg ctcttcgcac tttcagagtc 30
<210> 75
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 75
acgttggatg gcaataattt tcccactatc 30
<210> 77
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 77
acgttggatg tccatcgatt cttggtgttc 30
<210> 77
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 77
acgttggatg caaatttgtg tcttctgttc 30
<210> 78
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 78
acgttggatg ggatttgagc tgaggtcttc 30
<210> 79
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 79
acgttggatg cactgaaagc tatgcacaag 30
<210> 80
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 80
acgttggatg tagggccgca tttccaaaag 30
<210> 81
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 81
acgttggatg caggaaagaa cgctgagttg 30
<210> 82
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 82
acgttggatg gcttgcatag gcaagtgaca 30
<210> 83
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 83
acgttggatg gccatcaaca gctggtttct 30
<210> 84
<211> 30
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 84
acgttggatg cctctccaag atgagtactg 30
<210> 85
<211> 17
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 85
acccacaccc agagtaa 17
<210> 86
<211> 17
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 86
cttggcctta cctggat 17
<210> 87
<211> 17
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 87
agtgcagaaa ggcatat 17
<210> 88
<211> 18
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 88
tcccccgcct gtaccctt 18
<210> 89
<211> 18
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 89
gtggagattc tcaacaga 18
<210> 90
<211> 19
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 90
ctctgcgtta gcccctgtg 19
<210> 91
<211> 20
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 91
<210> 92
<211> 20
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 92
<210> 93
<211> 20
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 93
<210> 94
<211> 21
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 94
gacacgcatc tcccaccccc a 21
<210> 95
<211> 21
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 95
ggcatccttt gctgccctca c 21
<210> 96
<211> 22
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 96
tatacagtga ctttgctacc ct 22
<210> 97
<211> 22
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 97
acgctgtaaa catttaacaa ac 22
<210> 98
<211> 22
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 98
gcgccttgga aaaacgaagc ca 22
<210> 99
<211> 23
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 99
ccccacatct accatgcgtc ctg 23
<210> 100
<211> 23
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 100
tggggcacga ggtccagaga tac 23
<210> 101
<211> 24
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 101
accgcctcgg cgatccccgg cctg 24
<210> 102
<211> 24
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 102
gtcagagata gcaaaagttt aagc 24
<210> 103
<211> 24
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 103
agagggatga caatgaatgt gaca 24
<210> 104
<211> 25
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 104
agttcaagag ctcttttgtc tttca 25
<210> 105
<211> 25
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 105
gcttgatgag ctgctaactg agcac 25
<210> 106
<211> 25
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 106
caagagaaag gaatagaaag aatca 25
<210> 107
<211> 26
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 107
tttatcctac atctttaact aaaaat 26
<210> 108
<211> 17
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 108
ccttcgccaa ccactcc 17
<210> 109
<211> 17
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 109
gtcagccacc actatgc 17
<210> 110
<211> 17
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 110
gctgggctgc acgctac 17
<210> 111
<211> 17
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 111
cattcgcccg ggtcagg 17
<210> 112
<211> 18
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 112
ggcaagggct tcggggta 18
<210> 113
<211> 19
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 113
cctcctcaaa gtgctggtc 19
<210> 114
<211> 20
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 114
<210> 115
<211> 20
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 115
<210> 116
<211> 20
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 116
<210> 117
<211> 21
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 117
gcttatttac gcttgaacct c 21
<210> 118
<211> 21
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 118
atcgggcatg gagctcccgc a 21
<210> 119
<211> 22
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 119
gtaaatgatc agattcgcct tt 22
<210> 120
<211> 22
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 120
ttagaagaac tgtttcctac tg 22
<210> 121
<211> 23
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 121
cctatccttt actctaatca ctt 23
<210> 122
<211> 23
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 122
ttaagtaatt tgttatgggt tcc 23
<210> 123
<211> 24
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 123
cttttgtgtc ttctgttctc aaag 24
<210> 124
<211> 24
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 124
gggtaagggc ttcatagtca tata 24
<210> 125
<211> 25
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 125
tgccattatc ttcaaagact taatt 25
<210> 126
<211> 25
<212> DNA
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 126
aaacaaaacg taattgatta tattc 25
Claims (4)
1. A nucleic acid composition for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry is characterized in that: the nucleic acid composition comprises an upstream primer and a downstream primer of 42 SNP loci, wherein the 42 SNP loci are rs1799978, rs4986893, rs6444970, rs28371725, rs1051740, rs144012689, rs1135840, rs6295, rs4713916, rs389209, rs1045642, rs1414334, rs489693, rs3087374, rs762551, rs1057910, rs1799732, rs 929191, rs1471786, rs776746, rs35742686, rs 2304014016, rs1902023, rs5030865, rs16947, rs1065852, rs334558, rs 22354722, rs1800497, rs 169921385, rs 8922273, rs1061235, rs1799930, rs2011425, rs1079597, 951439, rs 383818, rs 12212744560, rs 1274497285, rs 799745974580, rs 11679727443, rs 11697443 443, rs 47443 443; the nucleic acid sequences of the upstream primer and the downstream primer of the 42 SNP sites are shown in SEQ ID NO. 1-84.
2. The nucleic acid composition for matrix-assisted laser desorption time-of-flight mass spectrometry detection of genes related to psychotropic drugs according to claim 1, wherein: the nucleic acid composition also comprises 42 extension primers, and the nucleic acid sequence of the extension primers is shown as SEQ ID NO. 85-126.
3. A kit for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry is characterized in that: comprising the nucleic acid composition of claim 1 or 2.
4. A detection method for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry is characterized in that: the method comprises the following steps:
s1, carrying out PCR amplification on a DNA sample by using the nucleic acid composition as claimed in claim 1 as a primer;
s2, carrying out SAP reaction on the amplification product obtained in the step S1;
s3, carrying out extension reaction on the reaction product of the step S2 by adopting the extension primer of claim 2;
and S4, desalting the sample obtained in the step S3, spotting the sample on a chip, and then performing matrix-assisted laser desorption time-of-flight mass spectrometry.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111134097.1A CN113755581A (en) | 2021-09-27 | 2021-09-27 | Nucleic acid composition, kit and method for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111134097.1A CN113755581A (en) | 2021-09-27 | 2021-09-27 | Nucleic acid composition, kit and method for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113755581A true CN113755581A (en) | 2021-12-07 |
Family
ID=78797676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111134097.1A Pending CN113755581A (en) | 2021-09-27 | 2021-09-27 | Nucleic acid composition, kit and method for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113755581A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117248013A (en) * | 2023-11-07 | 2023-12-19 | 瑞因生物科技(广州)有限公司 | Primer group and kit for detecting medicine for human chronic mental diseases and application of primer group and kit |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140274764A1 (en) * | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict response to treatments for mental disorders |
| CN110184345A (en) * | 2019-07-11 | 2019-08-30 | 南京先声医学检验有限公司 | For detecting primer sets, application, product and the method for spirit and neural class disease medication associated SNP positions |
| CN110331214A (en) * | 2019-07-19 | 2019-10-15 | 上海康黎医学检验所有限公司 | A kind of kit and its detection method for instructor's mental disease medication |
| CN111808943A (en) * | 2020-06-18 | 2020-10-23 | 重庆浦洛通基因医学研究院有限公司 | Gene detection method for individual medication of mental |
| US20210012882A1 (en) * | 2018-10-17 | 2021-01-14 | Tempus Labs | Data-based mental disorder research and treatment systems and methods |
| CN113192649A (en) * | 2021-06-01 | 2021-07-30 | 山东英盛生物技术有限公司 | System for guiding individualized and accurate medication of epileptic diseases |
-
2021
- 2021-09-27 CN CN202111134097.1A patent/CN113755581A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140274764A1 (en) * | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict response to treatments for mental disorders |
| US20210012882A1 (en) * | 2018-10-17 | 2021-01-14 | Tempus Labs | Data-based mental disorder research and treatment systems and methods |
| CN110184345A (en) * | 2019-07-11 | 2019-08-30 | 南京先声医学检验有限公司 | For detecting primer sets, application, product and the method for spirit and neural class disease medication associated SNP positions |
| CN110331214A (en) * | 2019-07-19 | 2019-10-15 | 上海康黎医学检验所有限公司 | A kind of kit and its detection method for instructor's mental disease medication |
| CN111808943A (en) * | 2020-06-18 | 2020-10-23 | 重庆浦洛通基因医学研究院有限公司 | Gene detection method for individual medication of mental |
| CN113192649A (en) * | 2021-06-01 | 2021-07-30 | 山东英盛生物技术有限公司 | System for guiding individualized and accurate medication of epileptic diseases |
Non-Patent Citations (1)
| Title |
|---|
| HAO YU ET AL.: "Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study", LANCET PSYCHIATRY, vol. 5, no. 4, pages 1 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117248013A (en) * | 2023-11-07 | 2023-12-19 | 瑞因生物科技(广州)有限公司 | Primer group and kit for detecting medicine for human chronic mental diseases and application of primer group and kit |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110184345B (en) | Primer group, application, product and method for detecting SNP (single nucleotide polymorphism) sites related to drug administration for mental and neurological diseases | |
| CN107022641B (en) | Primer for detecting deafness gene and application thereof | |
| CN114438200B (en) | Typing kit, primers and typing method for vitamin K metabolism related genes | |
| CN113755581A (en) | Nucleic acid composition, kit and method for detecting drug-related genes of mental diseases by matrix-assisted laser desorption time-of-flight mass spectrometry | |
| CN112280849B (en) | Composite amplification system and kit for anti-depression individualized medication genotyping detection | |
| CN113005196A (en) | Primer and probe composition for detecting turner syndrome, non-diagnostic detection method and kit | |
| Oberacher et al. | Profiling 627 Mitochondrial Nucleotides via the Analysis of a 23-Plex Polymerase Chain Reaction by Liquid Chromatography− Electrospray Ionization Time-of-Flight Mass Spectrometry | |
| CN110564836A (en) | Primer-probe combination for guiding detection of related genes for repaglinide drug personalized administration, kit and application | |
| CN111235252A (en) | Method for distinguishing individual medication of nitrendipine by mass spectrometry through detecting product | |
| CN116064853A (en) | Kit and application thereof | |
| CN109971841A (en) | The method and its application of gene mononucleotide polymorphism are detected by LC-MS | |
| CN113322317A (en) | Primer pair, probe set and kit for mitochondrial obesity gene mutation detection | |
| CN116179669B (en) | Typing kit, primer and typing method for vitamin B12 metabolism related genes | |
| CN110129432A (en) | A kind of detection method of personalized medicine related gene polymorphism | |
| CN113584151B (en) | Composite amplification system and kit for antipsychotic individualized medication related genotyping detection | |
| CN111235256A (en) | Detection kit for lacidipine medication guidance gene of antihypertensive drug | |
| CN111187820A (en) | Method for distinguishing Nistrol personalized medicine by detecting product and performing mass spectrometry | |
| CN111235255A (en) | Method for distinguishing individual medication of nitrendipine by using primer composition through mass spectrometry | |
| CN111197078A (en) | Method for distinguishing nifedipine personalized medicine by mass spectrometry through product detection | |
| CN111235253A (en) | Detection product for distinguishing nitrendipine individualized medication type | |
| CN111187822A (en) | Detection product for distinguishing individual drug type of Nicholol | |
| CN111172268A (en) | Method for distinguishing individual drug administration of verapamil by detecting product and performing mass spectrometry | |
| CN111235257A (en) | Method for distinguishing lacidipine personalized medicine by mass spectrometry through product detection | |
| CN111172266A (en) | Kit for detecting drug-using guide gene of antihypertensive drug verapamil | |
| CN113265460B (en) | Primer for detecting SLC26A4 point mutation of deafness gene and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |